European Regulator Suspends Glaxo’s Diabetes Drug Avandia

Just in:

The European Medicines Agency Thursday suspended marketing authorization for GlaxoSmithKline PLC’s (GSK) controversial diabetes drug rosiglitazone saying the risks of taking the drug don’t outweigh its benefits and that the medicines containing it will stop being available in Europe within the next few months.

The EMA — the decentralized European body responsible for licensing rosiglitazone in 2000 and which held an extraordinary expert meeting earlier this month to review the drug’s safety — said in a statement that “the availability of recent studies has added to the knowledge about rosiglitazone and overall, the accumulated data support an increased cardiovascular risk” from the drug.

The regulator said it therefore decided that “the benefits of rosiglitazone no longer outweigh its risks” and recommended the suspension of the marketing authorization of the medicines.

The decision affects the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim.

Pressure has increased for the London-based European body to pull the drug, which has been linked to heart failure, after U.K. regulators this month said the risks from taking Avandia were greater than the benefits. The Medicines and Healthcare products Regulatory Agency (MHRA) said it believed the risks of rosiglitazone outweighed its benefits and that “it no longer has a place on the U.K. market.”

Full story here at the Wall Street Journal


2 Responses to “European Regulator Suspends Glaxo’s Diabetes Drug Avandia”

  1. truthman30 Says:

    Simply amazing.. So Avandia is being pulled in Europe, but still available in the US market with restrictions, I guess that indicates which regulator has a closer bond with GSK.. Although I am pleased that Glaxo have been penalized with Avandia for the suppression of risks etc.. It makes me think of Seroxat, and why it wasn’t pulled? Seroxat has been even more controversial in many ways, but I guess its easier to pin point heart attacks and heart damage than Seroxat induced suicide and violence… And then again, who is there to document the individual Seroxat nightmares?.. Mental illness might be easier to exploit, maybe due to its subjective nature.. Perhaps also.. this is a little lesson from the European regulators after their disgraceful carry on with the Seroxat Scandal?.. Either way, it is good news for patients, but I can’t help being cynical, but who wouldn’t be?.. The pharmaceutical industry and drug regulation is as cynical as cynical gets.. What a shame it is so ..

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: